News about Drug Discovery & Development

Navigate BioPharma Services Unveils New Assay for Precise Measurement of Radioligand Therapies

Navigate BioPharma Services, Inc. has introduced a new assay for quantifying pharmacodynamic markers of radioligand therapies in tumors.

Drug Discovery & Development | 01/06/2024 | By Aishwarya |  440

ModeX Signs Master Services Deal with ProBioGen to Accelerate COVID-19 Antibody Development

ProBioGen has partnered with ModeX Therapeutics an OPKO Health Company, dedicated to combating cancer and infectious diseases with cutting-edge multi-specific biologics.

Drug Discovery & Development | 31/05/2024 | By Aishwarya |  688

Lexicon Selects Medidata to Advance First Non-Opioid Drug for Neuropathic Pain

Medidata has been chosen by Lexicon Pharmaceuticals, Inc. to help advance PROGRESS, a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain (DPNP), with the potential for LX9211 to become the first new, non-opioid drug approved for neuropathic pain in over two decades.

Drug Discovery & Development | 30/05/2024 | By Aishwarya |  518

Helsinn Signs License Deal with Angelini Pharma to Commercialize AULIN and MESULID

Helsinn Group has signed Distribution and Licence Agreement renewal with Angelini Pharma in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic for AULIN and MESULID (Nimesulide) for the treatment of acute (short-term) pain.

Drug Discovery & Development | 29/05/2024 | By Aishwarya |  940

Nona Biosciences Signs License Deal with AstraZeneca for Monoclonal Antibody Development

Nona Biosciences has signed a license deal with AstraZeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.

Drug Discovery & Development | 27/05/2024 | By Aishwarya |  470

DelSiTech Enters into Licensing Deal with Global Pharma Firm for Drug Delivery

DelSiTech Ltd. has entered into a Licensing Agreement with an undisclosed global pharmaceutical company.

Drug Discovery & Development | 23/05/2024 | By Aishwarya |  819

Cipla Gets Final FDA Approval for Lanreotide Injection

Cipla Ltd. has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from the United States Food and Drug Administration (US FDA).

Drug Discovery & Development | 23/05/2024 | By Aishwarya |  1664

Galapagos, BCA to Boost Decentralized CAR-T Manufacturing Network in US

Galapagos has inked a strategic partnership with Blood Centers of America (BCA) for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the US.

Drug Discovery & Development | 17/05/2024 | By Aishwarya |  344

Varian Announces US Distribution Agreement with Innova Vascular for New Innovative Thrombectomy Solutions

Venous thromboembolism (VTE) is a significant medical condition characterized by the formation of blood clots within the deep venous system.

Drug Discovery & Development | 16/05/2024 | By Manvi |  650

CASI Pharmaceuticals Advances CID-103 into Clinical Development for Chronic Immune Thrombocytopenia

CASI received a letter from the FDA indicating clearance for the study to proceed, signaling regulatory approval for the advancement of CID-103 into clinical trials.

Drug Discovery & Development | 16/05/2024 | By Abha |  818